Medscape2d
Benefits Outweigh Risks for Weight Loss Drug Mysimba
The benefits of naltrexone/bupropion (Mysimba) continue to outweigh its risks, despite ongoing uncertainty about long-term ...
Medscape4d
Faster Cancer Drug Approvals Tied to Clinical Benefits
Researchers analyzed pivotal and confirmatory trial characteristics, outcomes, and safety data for 102 cancer drug ...
BenefitsPRO3d
Weight management drugs now lead drug spending increases, study finds
Claims data also show rapid adoption of GLP-1 for weight loss, with a steady increase in utilization since 2021 and peaking ...
BioSpace2d
EU Rejects Lilly’s Alzheimer’s Drug Kisunla, Following Same Path as Rival Leqembi
The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...
CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug -- Update
Eli Lilly, which is seeking European approval of Kisunla for the treatment of early symptomatic Alzheimer's, said it will seek re-examination by CHMP. The Indianapolis drugmaker said it remains ...